

NCIC CLINICAL TRIALS GROUP

SARCOMA

NCIC CTG / CSG SARCOMA COMMITTEE MEETING AGENDA

Delta Chelsea Hotel, Toronto, ON

Sunday, May 4th, 2008 – 1:30 p.m. to 4:30 p.m.

Room: CARLYLE

Chair: V. Bramwell

1:30 P.M.	WELCOME & MINUTES FROM 2007APR29 MEETING	V. Bramwell
1:35 P.M.	REPORT FROM EXECUTIVE COMMITTEE <ul style="list-style-type: none">• NIH Grant Submission / Site Visit – 2008FEB26• CTEP GIST Taskforce• Leadership Sarcoma DSC – Succession Planning	V. Bramwell / R. Meyer
1:55 P.M. [20 mins]	INVITED PRESENTATIONS a) EURAMOS osteosarcoma study <i>Discussion</i>	A. Gupta
[45 mins]	b) Molecular targets in sarcoma / targeted therapies <i>Discussion</i>	T. Nielsen / Q. Chu
[30 mins]	c) Potential radiation studies <i>Discussion</i>	C. Catton / P. Ferguson
[20 mins]	d) Exercise intervention trial: Impact on quality of life <i>Discussion</i>	A. Davis
3:50 P.M.	STUDIES ONGOING / CLOSE TO ACTIVATION <ul style="list-style-type: none">• NCIC CTG / CSG SR5 / EORTC 62012 Dox vs. HD Dox / Ifos in advanced STS• NCIC CTG / CSG SRC5 / SWOG S0502 Imatinib ± bevacizumab in advanced GIST	S. Rorke K. Mulder
4:20 P.M.	COMPLETED STUDIES (PRESENTATIONS / PUBLICATIONS) <ul style="list-style-type: none">• NCIC CTG / CSG SR4 / SWOG S0033 Imatinib standard vs. high dose in advanced GIST• NCIC CTG / CSG SRC1 / ACOSOG Z9001 Adjuvant imatinib in GIST• NCIC CTG / CSG SR3 / EORTC 62931 Adjuvant Dox / Ifos vs. control in STS	V. Bramwell M. Blackstein V. Bramwell
	OTHER BUSINESS <ul style="list-style-type: none">• Connective Tissue Oncology Society (CTOS) Annual Meeting, London, England, November 13-15, 2008	
4:30 P.M.	MEETING ADJOURNED	